149 related articles for article (PubMed ID: 22897944)
21. Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
Decoster L; Vande Broek I; Neyns B; Majois F; Baurain JF; Rottey S; Rorive A; Anckaert E; De Mey J; De Brakeleer S; De Grève J
Anticancer Res; 2015 Dec; 35(12):6893-9. PubMed ID: 26637913
[TBL] [Abstract][Full Text] [Related]
22. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Cabuk D; Basaran G; Teomete M; Dane F; Korkmaz T; Seber S; Telli F; Yumuk PF; Turhal S
Asian Pac J Cancer Prev; 2014; 15(1):117-22. PubMed ID: 24528011
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Mackay HJ; Tinker A; Winquist E; Thomas G; Swenerton K; Oza A; Sederias J; Ivy P; Eisenhauer EA
Gynecol Oncol; 2010 Feb; 116(2):163-7. PubMed ID: 19740535
[TBL] [Abstract][Full Text] [Related]
25. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
26. New perspectives: role of sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2010; 161(5):475-82. PubMed ID: 20949248
[TBL] [Abstract][Full Text] [Related]
27. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
Koh Y; Lee HE; Im SA; Kim SH; Kim TM; Han SW; Oh DY; Kim JH; Lee SH; Kim DW; Kim TY; Kim WH; Heo DS; Bang YJ
Diagn Mol Pathol; 2011 Sep; 20(3):143-7. PubMed ID: 21817899
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J; González-Larriba JL; Prior C; Maroto P; Carles J; Castellano D; Mellado B; Gallardo E; Perez-Gracia JL; Aguilar G; Villanueva X; Albanell J; Calvo A
Ann Oncol; 2011 Dec; 22(12):2646-2653. PubMed ID: 21427062
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of sunitinib malate in patients with recurrent high-grade glioma.
Neyns B; Sadones J; Chaskis C; Dujardin M; Everaert H; Lv S; Duerinck J; Tynninen O; Nupponen N; Michotte A; De Greve J
J Neurooncol; 2011 Jul; 103(3):491-501. PubMed ID: 20872043
[TBL] [Abstract][Full Text] [Related]
32. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
[TBL] [Abstract][Full Text] [Related]
33. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Zhu AX; Duda DG; Ancukiewicz M; di Tomaso E; Clark JW; Miksad R; Fuchs CS; Ryan DP; Jain RK
Clin Cancer Res; 2011 Feb; 17(4):918-27. PubMed ID: 20843836
[TBL] [Abstract][Full Text] [Related]
34. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Sahani DV; Jiang T; Hayano K; Duda DG; Catalano OA; Ancukiewicz M; Jain RK; Zhu AX
J Hematol Oncol; 2013 Jul; 6():51. PubMed ID: 23842041
[TBL] [Abstract][Full Text] [Related]
36. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
37. Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.
Powles T; Chowdhury S; Shamash J; Bazeos A; Gillessen S; Saunders N; Lim L; Sarwar N; Sadev A; Wilson P; Nathan P; Boleti K; Peters J; Agrawal S
Ann Oncol; 2011 Apr; 22(4):815-820. PubMed ID: 20943595
[TBL] [Abstract][Full Text] [Related]
38. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
39. [Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
Zhao X; Meng XY; Sun B; Ding LJ; Jiang ZF; Song ST; Wu SK
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):96-8. PubMed ID: 23648343
[TBL] [Abstract][Full Text] [Related]
40. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]